APA (7th ed.) Citation

Satwani, P., Jin, Z., Martin, P. L., Bhatia, M., Garvin, J. H., George, D., . . . Cairo, M. S. (2015). Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. Leukemia (08876924), 29(2), 448. https://doi.org/10.1038/leu.2014.194

Chicago Style (17th ed.) Citation

Satwani, P., et al. "Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Is Safe and Feasible in Children, Adolescents and Young Adults with Poor-risk Refractory or Recurrent Hodgkin and Non-Hodgkin Lymphoma." Leukemia (08876924) 29, no. 2 (2015): 448. https://doi.org/10.1038/leu.2014.194.

MLA (9th ed.) Citation

Satwani, P., et al. "Sequential Myeloablative Autologous Stem Cell Transplantation and Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Is Safe and Feasible in Children, Adolescents and Young Adults with Poor-risk Refractory or Recurrent Hodgkin and Non-Hodgkin Lymphoma." Leukemia (08876924), vol. 29, no. 2, 2015, p. 448, https://doi.org/10.1038/leu.2014.194.